Cell Therapeutics Pays Up In Off-Label Marketing Case

Law360, New York (April 17, 2007, 12:00 AM EDT) -- Cell Therapeutics Inc. has agreed to shell out $10.5 million to resolve claims that it promoted its leukemia treatment for uses not cleared first with the U.S. Food and Drug Administration.

The U.S. Department of Justice said Tuesday the Seattle, Wash.-based cancer drug manufacturer settled allegations that it illegally marketed Trisenox for the treatment of various forms of cancer. The FDA did not approve these uses of the drug and they had not been proven safe or effective.

Cell Therapeutics revealed preliminary terms of the settlement...
To view the full article, register now.